Amélie Penot

Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients

David Y. Léger, Stéphane Moreau, N. Signol et al. · Journal of Geriatric Oncology · 2017 · 40 citations

Medicine, Hematology, Pharmacology +17

Factors associated with the designation of a health care proxy and writing advance directives for patients suffering from haematological malignancies

S. Trarieux-Signol, Stéphane Moreau, Marie-Pierre Gourin et al. · BMC Palliative Care · 2014 · 36 citations · Full text

Law, Health Law, End-of-life Care +12

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 ⁺ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Thibaut Leguay, Marc Delord, Cyril Šálek et al. · Journal of Clinical Oncology · 2024 · 34 citations

Medicine, Hematology, Oncology +16

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

François Guilhot, Françoise Rigal‐Huguet, Joëlle Guilhot et al. · Leukemia · 2021 · 31 citations

Pharmacy, Hematology, Pharmacotherapy +14

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980–2009

Amélie Penot, Pierre‐Marie Preux, Sandra Le Guyader et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 17 citations

Medicine, Hematology, Oncology +13